Mark Altmeyer - Myovant Sciences Independent Director
| MYOVDelisted Stock | USD 26.98 0.01 0.04% |
Director
Mr. Mark Altmeyer is an Independent Director of Myovant Sciences Ltd. Since March 2015, Mr. Altmeyer has served as the President and Chief Commercial Officer of Axovant Sciences, Inc., a whollyowned subsidiary of Axovant Sciences Ltd. From February 2009 to December 2014, Mr. Altmeyer served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc. Prior to his time at Otsuka, Mr. Altmeyer served in a number of executive leadership roles at BristolMyers Squibb, including Senior Vice President, Global Commercialization from 2006 to 2008 and Senior Vice President, Neuroscience Business Unit from 2002 to 2005 during the approval and launch of Abilify, a branded drug used to treat multiple psychiatric conditions, including schizophrenia, depression and bipolar disorder since 2016.
| Age | 55 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 44 20 7400 3351 |
| Web | https://myovant.com |
Myovant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Myovant Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Myovant Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myovant Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myovant to invest in growth at high rates of return. When we think about Myovant Sciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Pertti Voutilainen | Agnico Eagle Mines | 76 | |
| Ted Gardner | Summit Materials | 61 | |
| Martine Celej | Agnico Eagle Mines | 55 | |
| Susan Ellerbusch | Summit Materials | 53 | |
| Bernard Kraft | Agnico Eagle Mines | 83 | |
| Mel Leiderman | Agnico Eagle Mines | 67 | |
| Robert Gemmell | Agnico Eagle Mines | 64 | |
| Anne Cooney | Summit Materials | 61 | |
| Jamie Sokalsky | Agnico Eagle Mines | 63 | |
| Steven Wunning | Summit Materials | 70 | |
| Leona Aglukkaq | Agnico Eagle Mines | 54 | |
| Leanne Baker | Agnico Eagle Mines | 66 | |
| Anne Wade | Summit Materials | 48 | |
| Deborah McCombe | Agnico Eagle Mines | 67 | |
| Neil Simpkins | Summit Materials | 51 | |
| Howard Stockford | Agnico Eagle Mines | 74 | |
| Joseph Cantie | Summit Materials | 57 | |
| John Murphy | Summit Materials | 70 | |
| John Roberts | Agnico Eagle Mines | 71 | |
| Sean Riley | Agnico Eagle Mines | 66 | |
| Julia Kahr | Summit Materials | 37 | |
Management Performance
| Return On Asset | -0.18 |
Myovant Sciences Leadership Team
Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. | ||
| Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc | ||
| Mark Altmeyer, Independent Director | ||
| Nancy Valente, Director | ||
| Kim Sablich, Chief Commercial Officer | ||
| Adele Gulfo, Director, Interim Chief Commercial Officer | ||
| Myrtle Potter, Chairman of the Board | ||
| Terrie Curran, Independent Director | ||
| Lauren Merendino, Chief Commercial Officer | ||
| Keith Manchester, Director | ||
| Marianne Romeo, Head, Global Transactions & Risk Management | ||
| Ann Tomlin, VP HR | ||
| Juan MD, Chief Officer | ||
| Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer | ||
| Frank Torti, Director | ||
| Andria MD, Head Pharmacovigilance | ||
| Matthew JD, Gen Sec | ||
| Vivek Ramaswamy, Director | ||
| Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development | ||
| Albert Liao, Director Communications | ||
| Wayne DeVeydt, Independent Director | ||
| Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. | ||
| Kathleen Sebelius, Lead Independent Director | ||
| Mark Guinan, Independent Director | ||
| David Marek, Principal Executive Officer, Director | ||
| Hiroshi Nomura, Director | ||
| Bryan Selby, VP Devel | ||
| Lynn Seely, Principal Executive Officer, Director |
Myovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.48) % | |||
| Operating Margin | (0.39) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 97.26 M | |||
| Shares Owned By Insiders | 48.61 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Number Of Shares Shorted | 8.39 M | |||
| Price To Earning | (8.56) X | |||
| Price To Book | 70.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myovant Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myovant Sciences' short interest history, or implied volatility extrapolated from Myovant Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Myovant Stock
If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |